| Attending joint formulation meetings on pharmaceuticals and special medical materials. | Kræft
> Kræft: de fleste typer | Regulatorisk partnerskab
> Arbejde med regulerende myndigheder | 100.000 | National | Sometimes | 119017792133 |
| At year-end, regulatory authorities, cancer patient advocacy groups, and clinical physicians are invited to review the NHI [全民健康保險 – National Health Insurance] reimbursement policies for that year. | Kræft
> Kræft: de fleste typer | Regulatorisk partnerskab
> Arbejde med regulerende myndigheder | 5.000 | National | Sometimes | 119022421395 |
| Convene an annual year-end review bringing together regulatory authorities, cancer patient advocacy organisations, and clinical physicians to evaluate the NHI reimbursement policies for that calendar year. Patient advocacy groups present on unmet patient needs, clinicians conduct a cancer-type-specific assessment of the gaps between Taiwan's NHI [全民健康保險 – National Health Insurance] reimbursement coverage and oncology treatment guidelines, and dialogue is facilitated with the regulatory authorities. | Kræft
> Kræft: de fleste typer | Regulatorisk partnerskab
> Deltag i Health Technology Assessment (HTA) og refusionsgennemgange | 5.000 | National | Sometimes | 119022421395 |
| We communicate patient needs to the National Health Insurance Administration in order to improve patient access to treatment. | Neuromuskulær
> Spinal muskelatrofi (SMA) | Regulatorisk partnerskab
> Deltag i Health Technology Assessment (HTA) og refusionsgennemgange | 100 | National | Regularly | 119053648739 |
| Convene an annual year-end review bringing together regulatory authorities, cancer patient advocacy organisations, and clinical physicians to evaluate the NHI reimbursement policies for that calendar year. Patient advocacy groups present on unmet patient needs, clinicians conduct a cancer-type-specific assessment of the gaps between Taiwan's NHI [全民健康保險 – National Health Insurance] reimbursement coverage and oncology treatment guidelines, and dialogue is facilitated with the regulatory authorities. | Kræft
> Kræft: de fleste typer | Regulatorisk partnerskab
> Deltag i/faciliter møder med politiske beslutningstagere/regulatorer | 5.000 | National | Sometimes | 119022421395 |
| At year-end, regulatory authorities, cancer patient advocacy groups, and clinical physicians are invited to review the NHI [全民健康保險 – National Health Insurance/Taiwan] reimbursement policies for that year. | Kræft
> Kræft: de fleste typer | Regulatorisk partnerskab
> Deltag i/faciliter møder med politiske beslutningstagere/regulatorer | 5.000 | National | Sometimes | 119022421395 |
| ... Since 2025, the government [in Taiwan] has also begun implementing its Cancer New Drug Fund policy, and our organisation is recognised as one of 13 patient advocacy groups whose efforts contributed to that successful outcome. | Kræft
> Kræft: de fleste typer | Indflydelse på politik og lovgivning
> Påvirk sundhedspolitik og lovgivning | 10.000 | National | Sometimes | 119055308347 |
| With regard to pricing, we have not had the opportunity to participate in discussions, as prices are largely determined by pharmaceutical companies' global headquarters, with patient advocacy groups afforded no meaningful role in the process. Nevertheless, we actively present patients' clinical medication needs to the government in cases where reimbursement under Taiwan's NHI [全民健康保險 – National Health Insurance] is unavailable, with the aim of securing alternative funding mechanisms to support cancer patients — such as a dedicated cancer medicines fund. | Kræft
> Kræft: de fleste typer | Indflydelse på politik og lovgivning
> Deltag i offentlige høringer og konsultationer | 10.000 | National | Sometimes | 119055325391 |
| To advocate for the expansion of reimbursement coverage for new medicines to encompass broader therapeutic indications. | Generelt helbred
> Levering af sundhedsydelser | Prisfastsættelse og overkommelighed
> Fortaler for retfærdig medicinprissætning | 5.000 | National | Sometimes | 119051396882 |
| We are advocating for the inclusion of immunotherapy for early-stage triple-negative breast cancer patients within the reimbursement coverage of the National Health Insurance scheme. | Kræft
> Kræft: bryst | Prisfastsættelse og overkommelighed
> Fortalelse af optagelse af produktet på refusionslister/nationale formularer | 10.000 | National | Regularly | 119016883314 |
| To advocate for the expansion of reimbursement coverage for new medicines to encompass broader therapeutic indications. | Generelt helbred
> Levering af sundhedsydelser | Prisfastsættelse og overkommelighed
> Fortalelse af optagelse af produktet på refusionslister/nationale formularer | 5.000 | National | Sometimes | 119051396882 |
| Advocating for the expansion of reimbursement coverage for new medicines to encompass broader indications. | Kræft
> Cancer: neuroendokrin (NET) | Prisfastsættelse og overkommelighed
> Fortalelse af optagelse af produktet på refusionslister/nationale formularer | 100 | National | Sometimes | 119051407743 |
| With regard to pricing, we have not had the opportunity to participate in discussions, as prices are largely determined by pharmaceutical companies' global headquarters, with patient advocacy groups afforded no meaningful role in the process. Nevertheless, we actively present patients' clinical medication needs to the government in cases where reimbursement under Taiwan's NHI [全民健康保險 – National Health Insurance] is unavailable, with the aim of securing alternative funding mechanisms to support cancer patients — such as a dedicated cancer medicines fund. | Kræft
> Kræft: de fleste typer | Prisfastsættelse og overkommelighed
> Fortalelse af optagelse af produktet på refusionslister/nationale formularer | 10.000 | National | Sometimes | 119055325391 |
| We are advocating for the inclusion of immunotherapy for early-stage triple-negative breast cancer patients within the reimbursement coverage of the National Health Insurance scheme. | Kræft
> Kræft: bryst | Forbedring af adgangsveje
> Fremme retfærdig adgang til medicin/sundhedspleje | 10.000 | National | Regularly | 119016883314 |
| Advocating for the expansion of reimbursement coverage for new medicines to encompass broader indications. | Kræft
> Cancer: neuroendokrin (NET) | Forbedring af adgangsveje
> Fremme retfærdig adgang til medicin/sundhedspleje | 100 | National | Sometimes | 119051407743 |
| We communicate patient needs to the National Health Insurance Administration in order to improve patient access to treatment. | Neuromuskulær
> Spinal muskelatrofi (SMA) | Forbedring af adgangsveje
> Fremme retfærdig adgang til medicin/sundhedspleje | 100 | National | Regularly | 119053648739 |
| In advocating for patient rights and access to new medicines, we engage with stakeholders, government authorities, and relevant experts to communicate patients' clinical needs and the urgency of treatment. | Kræft
> Kræft: de fleste typer | Forbedring af adgangsveje
> Fremme retfærdig adgang til medicin/sundhedspleje | 10.000 | National | Sometimes | 119055308347 |
| Convene an annual year-end review bringing together regulatory authorities, cancer patient advocacy organisations, and clinical physicians to evaluate the NHI reimbursement policies for that calendar year. Patient advocacy groups present on unmet patient needs, clinicians conduct a cancer-type-specific assessment of the gaps between Taiwan's NHI [全民健康保險 – National Health Insurance] reimbursement coverage and oncology treatment guidelines, and dialogue is facilitated with the regulatory authorities. | Kræft
> Kræft: de fleste typer | Evidensbaseret patientinput
> Brug patientindsigt til at informere beslutninger | 5.000 | National | Sometimes | 119022421395 |
| We serve as members of the Infected Persons Rights Protection Committee under Taiwan CDC [Centers for Disease Control]. | HIV
> HIV | Institutionel styring
> Sikre repræsentation i statslige rådgivende organer | 5.000 | National | Regularly | 119021698989 |
| In advocating for patient rights and access to new medicines, we engage with stakeholders, government authorities, and relevant experts to communicate patients' clinical needs and the urgency of treatment. | Kræft
> Kræft: de fleste typer | Institutionel styring
> Effektivt arbejde i netværk med flere interessenter | 10.000 | National | Sometimes | 119055308347 |